Revvity Announces Financial Results for the Third Quarter of 2025

Original from: Revvity

Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025.

The Company reported GAAP earnings per share of $0.40, as compared to $0.77 in the same period a year ago. Revenue for the quarter was $699 million, as compared to $684 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $82 million, as compared to $98 million for the same period a year ago. GAAP operating profit margin from continuing operations was 11.7% as a percentage of revenue, as compared to 14.3% in the same period a year ago.

Adjusted earnings per share from continuing operations for the quarter was $1.18, as compared to $1.28 in the same period a year ago. Adjusted operating income was $182 million, as compared to $193 million for the same period a year ago. Adjusted operating profit margin was 26.1% as a percentage of revenue, as compared to 28.3% in the same period a year ago.

Adjustments for the Company’s non-GAAP financial measures have been noted in the attached reconciliations.

“We performed well during the third quarter as a number of key innovations and strategic partnerships have begun to come to fruition,” said Prahlad Singh, president and chief executive officer of Revvity. “Our strong level of execution is positioning the Company for even greater success in 2026 and beyond.”

Share Repurchase Authorization

The Company’s Board of Directors has authorized a new two-year $1 billion share repurchase program which replaces the remainder of the prior repurchase program which was announced in October 2024.

Financial Overview by Reporting Segment

Life Sciences

Third quarter 2025 revenue was $343 million, as compared to $339 million in the same period a year ago. Revenue increased 1% and organic revenue was flat as compared to the same period a year ago.

Third quarter 2025 adjusted operating income was $101 million, as compared to $111 million in the same period a year ago. Adjusted operating profit margin was 29.5% as a percentage of revenue, as compared to 32.6% in the same period a year ago.

Diagnostics

Third quarter 2025 revenue was $356 million, as compared to $345 million in the same period a year ago. Revenue increased 3% and organic revenue increased 2% as compared to the same period a year ago.

Third quarter 2025 adjusted operating income was $89 million, as compared to $94 million in the same period a year ago. Adjusted operating profit margin was 25.1% as a percentage of revenue, as compared to 27.2% in the same period a year ago.

Full Year 2025 Guidance

For the full year 2025, the Company is updating its full year revenue guidance to $2.83-$2.88 billion to reflect recent changes in foreign currency exchange rates and is reaffirming its organic growth guidance of 2% to 4%. The Company is also raising its adjusted EPS guidance to a range of $4.90 to $5.00.

Guidance for the full year 2025 for adjusted EPS and organic growth is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.

Source: Revvity Announces Financial Results for the Third Quarter of 2025